- Home
- KALU vs AGIO Comparison
KALU vs AGIO Comparison
Compare KALU & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- AGIO
- Stock Information
- Founded
- KALU 1946
- AGIO 2007
- Country
- KALU United States
- AGIO United States
- Employees
- KALU N/A
- AGIO N/A
- Industry
- KALU Metal Fabrications
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- KALU Industrials
- AGIO Health Care
- Exchange
- KALU Nasdaq
- AGIO Nasdaq
- Market Cap
- KALU 1.2B
- AGIO 1.4B
- IPO Year
- KALU 1991
- AGIO 2013
- Fundamental
- Price
- KALU $79.96
- AGIO $33.65
- Analyst Decision
- KALU Buy
- AGIO Buy
- Analyst Count
- KALU 3
- AGIO 6
- Target Price
- KALU $69.00
- AGIO $58.60
- AVG Volume (30 Days)
- KALU 110.1K
- AGIO 611.7K
- Earning Date
- KALU 07-23-2025
- AGIO 07-31-2025
- Dividend Yield
- KALU 3.85%
- AGIO N/A
- EPS Growth
- KALU 0.39
- AGIO N/A
- EPS
- KALU 3.06
- AGIO 11.45
- Revenue
- KALU $3,063,900,000.00
- AGIO $37,035,000.00
- Revenue This Year
- KALU $11.04
- AGIO $22.30
- Revenue Next Year
- KALU $7.33
- AGIO $219.19
- P/E Ratio
- KALU $26.09
- AGIO $2.86
- Revenue Growth
- KALU 1.56
- AGIO 25.96
- 52 Week Low
- KALU $46.81
- AGIO $23.42
- 52 Week High
- KALU $100.07
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- KALU 68.13
- AGIO 54.30
- Support Level
- KALU $75.76
- AGIO $32.53
- Resistance Level
- KALU $77.75
- AGIO $35.88
- Average True Range (ATR)
- KALU 2.25
- AGIO 1.36
- MACD
- KALU -0.27
- AGIO -0.30
- Stochastic Oscillator
- KALU 95.21
- AGIO 29.02
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.